Cargando…
The Use of the Chuang's Prognostic Scale to Predict the Survival of Metastatic Colorectal Cancer Patients Receiving Palliative Systemic Anticancer Therapy
BACKGROUND: With the increasing number of agents active against cancer, advanced cancer patients including metastatic colorectal cancer (mCRC) patients may continue receiving palliative systemic anticancer therapy (PSAT) near the end-of-life. Validated palliative prognostic models, such as the Chuan...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973493/ https://www.ncbi.nlm.nih.gov/pubmed/27559261 http://dx.doi.org/10.4103/0973-1075.185043 |
_version_ | 1782446407007862784 |
---|---|
author | Alsirafy, Samy A Zaki, Omar Sakr, Amr Y Farag, Dina E El-Sherief, Wessam A Mohammed, Abha A |
author_facet | Alsirafy, Samy A Zaki, Omar Sakr, Amr Y Farag, Dina E El-Sherief, Wessam A Mohammed, Abha A |
author_sort | Alsirafy, Samy A |
collection | PubMed |
description | BACKGROUND: With the increasing number of agents active against cancer, advanced cancer patients including metastatic colorectal cancer (mCRC) patients may continue receiving palliative systemic anticancer therapy (PSAT) near the end-of-life. Validated palliative prognostic models, such as the Chuang's prognostic scale (CPS), may be helpful in identifying mCRC patients with limited survival who are unlikely to benefit from PSAT. AIM: To test the ability of the CPS to predict the survival of mCRC under treatment with PSAT. METHODS: CPS was prospectively assessed in 36 mCRC patients who were receiving PSAT. The scale is based on eight items: ascites, edema, cognitive impairment, liver and lung metastases, performance status, tiredness, and weight loss. The total CPS score ranges from 0 to 8.5 with the higher score indicating worse prognosis. RESULTS: Patients were divided into two groups using a CPS cutoff score of 5, Group 1 with a CPS score ≤5 and Group 2 with a CPS score >5. Using this cutoff value, 3-month mortality was predicted with a positive predictive value of 71%, a negative predictive value of 77%, a sensitivity of 67%, a specificity of 81% and an overall accuracy of 75%. Group 1 patients had a longer median survival of 149 days (95% confidence interval [CI]: 82-216) in comparison to Group 2 patients who had a median survival of 61 days (95% CI: 35-87). The difference in survival was statistically significant (P = 0.01). CONCLUSION: CPS may be useful in identifying mCRC patients with limited survival who are unlikely to benefit from PSAT. |
format | Online Article Text |
id | pubmed-4973493 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-49734932016-08-24 The Use of the Chuang's Prognostic Scale to Predict the Survival of Metastatic Colorectal Cancer Patients Receiving Palliative Systemic Anticancer Therapy Alsirafy, Samy A Zaki, Omar Sakr, Amr Y Farag, Dina E El-Sherief, Wessam A Mohammed, Abha A Indian J Palliat Care Original Article BACKGROUND: With the increasing number of agents active against cancer, advanced cancer patients including metastatic colorectal cancer (mCRC) patients may continue receiving palliative systemic anticancer therapy (PSAT) near the end-of-life. Validated palliative prognostic models, such as the Chuang's prognostic scale (CPS), may be helpful in identifying mCRC patients with limited survival who are unlikely to benefit from PSAT. AIM: To test the ability of the CPS to predict the survival of mCRC under treatment with PSAT. METHODS: CPS was prospectively assessed in 36 mCRC patients who were receiving PSAT. The scale is based on eight items: ascites, edema, cognitive impairment, liver and lung metastases, performance status, tiredness, and weight loss. The total CPS score ranges from 0 to 8.5 with the higher score indicating worse prognosis. RESULTS: Patients were divided into two groups using a CPS cutoff score of 5, Group 1 with a CPS score ≤5 and Group 2 with a CPS score >5. Using this cutoff value, 3-month mortality was predicted with a positive predictive value of 71%, a negative predictive value of 77%, a sensitivity of 67%, a specificity of 81% and an overall accuracy of 75%. Group 1 patients had a longer median survival of 149 days (95% confidence interval [CI]: 82-216) in comparison to Group 2 patients who had a median survival of 61 days (95% CI: 35-87). The difference in survival was statistically significant (P = 0.01). CONCLUSION: CPS may be useful in identifying mCRC patients with limited survival who are unlikely to benefit from PSAT. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC4973493/ /pubmed/27559261 http://dx.doi.org/10.4103/0973-1075.185043 Text en Copyright: © Indian Journal of Palliative Care http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Alsirafy, Samy A Zaki, Omar Sakr, Amr Y Farag, Dina E El-Sherief, Wessam A Mohammed, Abha A The Use of the Chuang's Prognostic Scale to Predict the Survival of Metastatic Colorectal Cancer Patients Receiving Palliative Systemic Anticancer Therapy |
title | The Use of the Chuang's Prognostic Scale to Predict the Survival of Metastatic Colorectal Cancer Patients Receiving Palliative Systemic Anticancer Therapy |
title_full | The Use of the Chuang's Prognostic Scale to Predict the Survival of Metastatic Colorectal Cancer Patients Receiving Palliative Systemic Anticancer Therapy |
title_fullStr | The Use of the Chuang's Prognostic Scale to Predict the Survival of Metastatic Colorectal Cancer Patients Receiving Palliative Systemic Anticancer Therapy |
title_full_unstemmed | The Use of the Chuang's Prognostic Scale to Predict the Survival of Metastatic Colorectal Cancer Patients Receiving Palliative Systemic Anticancer Therapy |
title_short | The Use of the Chuang's Prognostic Scale to Predict the Survival of Metastatic Colorectal Cancer Patients Receiving Palliative Systemic Anticancer Therapy |
title_sort | use of the chuang's prognostic scale to predict the survival of metastatic colorectal cancer patients receiving palliative systemic anticancer therapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973493/ https://www.ncbi.nlm.nih.gov/pubmed/27559261 http://dx.doi.org/10.4103/0973-1075.185043 |
work_keys_str_mv | AT alsirafysamya theuseofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy AT zakiomar theuseofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy AT sakramry theuseofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy AT faragdinae theuseofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy AT elsheriefwessama theuseofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy AT mohammedabhaa theuseofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy AT alsirafysamya useofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy AT zakiomar useofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy AT sakramry useofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy AT faragdinae useofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy AT elsheriefwessama useofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy AT mohammedabhaa useofthechuangsprognosticscaletopredictthesurvivalofmetastaticcolorectalcancerpatientsreceivingpalliativesystemicanticancertherapy |